Introduction
Over the past 20 years the existing directives for medical devices (Council Directive 93/42/EEC on medical devices [1] and Council Directive 90/385/EEC on active implantable medical devices [2] ) aim for a well-working internal market and a high level of safety for human health. Although existing regulatory frameworks have been approved, they were also fiercely criticized. These frameworks dealing with innovative products having a wide spectrum (dealing with bandages as well as pacemakers) of course need continuous revisions. In addition the directive was recently criticized by media and politics because of a critical incident with a French manufacturer (PIP scandal). The European commission reacted and in September 2012 they presented a proposal for a revised medical devices directive [3] . It is expected that in the next years this proposal will become binding and crucial changes and suggestions, which are addressed in the paper, could be an enormous challenge for various stakeholders.
Scope, changes and concepts
The scope of medical devices covered by the proposal generally includes the present combined scope of the directives 90/385/EEC (AIMDD) and 93/42/EEC (MDD). Some additions regarding inclusion and exclusion of special devices have been made. For example this affects products manufactured utilizing non-viable human tissues or cells, implantable or other invasive products without a medical purpose (but similar to medical devices in terms or characteristics and risk profile).
The classification of medical devices in four classes (I, IIa, IIb, III) regarding the potential risk will remain unaffected. The classification rules were updated and comprise 21 rules in the actual proposal. The conformity classes of several products are regulated accurately. All implantable medical devices and their accessories will be classified in conformity class III, this also applies for products using nanomaterial and apheresis machines.
One of the main topics of the proposal is the instrument "common technical specifications", which should further specify the general requirements, requirements on clinical evaluation and post-market clinical follow-up. Furthermore, on the one hand legal obligations depend on the potential risk class of the product, but on the other hand all manufactures are bound to implement and maintain a quality management system.
The proposal also introduces the following new concepts:
It includes the requirement that the manufacturer has to nominate a "qualified person" which is responsible for regulatory compliance. It tries to clarify responsibilities regarding the parallel trade problem (relabeling).
The reprocessing of single-use devices will be rated as the same process as manufacturing a new product. The re-processor must comply with the identical requirements as the manufacturer. Implant cards for patients using implants, including necessary information (Identification of the device, warnings, precautions etc.) must be provided by the manufacturer.
Another main topic concerns about the lack of transparency on the European medical device market, which will lead to an expansion of the requirements for identification and traceability of devices. Following actions will be executed: Identification of suppliers and customers of the manufacturer by request of national agencies. Providing manufacturers with a Unique Device Identification (UDI) for their products to achieve better traceability. Self-Registration of manufacturers and authorized representatives and their devices placed on the European market in the Central European database (EUDAMED).
Public access to data concerning information on safety, performance and clinical data of high risk devices. Online registration of clinical trials. A portal for reports of serious incidents and their corrective actions conducted by their manufacturers.
Another target of the revision is to harmonize the designation and monitoring of the notified bodies. Further they are committed to inform an established medical device coordination group (MCDG) of new applicants for conformity assessment of high risk devices. This control mechanism allows the MDCG to have a closer look on special devices before they are placed on the European market. On the other side the notified bodies receive more competence to carry out unannounced factory and device inspections.
Discussion and Conclusion
The proposal of the revision of the European legislation for medical products points out that the manufacturers must take more responsibility regarding transparency and traceability of the medical devices he places on the European market.This is indicated by the nomination of a "qualified person", the tightening of the traceability of the suppliers and the implementation of the UDI-number. Additional requirements on clinical evaluation and postmarket clinical follow-up underline these aspects. The instrument of unannounced factory and device inspections by Notified Bodies seems to be an attempt to force the manufacturer to implement the quality management system in daily working routines and not only for the annual announced audit.
This proposal will also be applicable for a group of manufacturers (implantable products without a medical purpose) which were not affected by the medical directive by now. It is a further attempt to decrease the grey area of some product groups which are not assignable to a specific directive. This is a chance for these manufacturers for clear production and quality guidelines and legal security.
Based on the quality management concept of continual improvements and the recently occurred critical incidents, the revision of the medical device regulations can be seen as a positive progress in principle. However, suggested topics and concepts have to be discussed with all stakeholders under consideration of the main objective of a high level of safety for human health. The impact of additional expenses (e.g. quality management systems) for medical device manufacturers due to the modifications of the medical device directive has to be included as well.
